Introduction
The phosphatidylinositol-3-kinase (PI3K) signaling pathway is important for the growth and survival of cancer cells in many different types of human malignancy, including breast and prostate cancer (1) (2) (3) . This pathway receives upstream input from ligand-receptor interactions and signals through downstream effectors (4) .
Mammalian target of rapamycin (mTOR) is a downstream effector molecule that
regulates the production of proteins critical for cell cycle progression and other important cellular growth processes (5) . Dysregulation of the PI3K axis is common in human cancer, and can be due to several mechanisms including overactive growth factor receptor signaling, activating mutations of PI3K, loss of function of the phosphatase and tensin homolog (PTEN) tumor suppressor, and overactivation of mTOR kinase activity (1).
The PI3K-Akt pathway lies downstream of the most common growth factor tyrosine kinase receptors implicated in cancer, and the pathway is a suspected driver of tumor progression in many cancers (4, 6) . Akt protein kinase is activated in the majority of human solid tumors, and appears to play a key role in tumor cell survival, contributing to tumor cell escape of apoptosis induced by cytotoxic, radiation, and targeted therapies (1, 4, 6) . Furthermore, constitutive or residual Akt activation is often found in tumor cells that have developed resistance to conventional chemotherapy, radiation, or targeted agents (7) . Therefore, inhibition of this critical cell survival pathway by an Akt inhibitor is hypothesized to synergize with multiple cancer treatment modalities to maximize tumor cell killing effect (8, 9) . Ridaforolimus, a non-prodrug analog of rapamycin that inhibits mTOR, has demonstrated antiproliferative activity in a broad range of human tumor cell lines in vitro and in murine tumor xenograft models (10) (11) (12) (13) . Ridaforolimus has been evaluated as single-agent or combination therapy for pediatric and adult patients with advanced malignancies by both the intravenous and oral routes of administration (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Ridaforolimus has demonstrated a favorable safety profile, mTOR inhibition, and antitumor activity in a broad range of cancers (3, 11) .
MK-2206 is a highly selective, oral allosteric Akt inhibitor, which is equally potent towards purified recombinant human Akt1 and Akt2 and approximately 5-fold less potent against human Akt3 (IC 50 = 8, 12 , and 65 nM, respectively) in enzyme assays, and is well tolerated as a single-agent (25) (26) (27) . In the first-in-humans clinical trial of MK-2206 in advanced solid tumors, 33 patients received MK-2206 at 30, 60, 75, or 90 mg on alternating days. Dose-limiting toxicities (DLT) included skin rash and stomatitis, establishing the maximum tolerated dose (MTD) at 60 mg every other day (26) . In another phase I trial, a once-weekly (QW) schedule of MK-2206 was found to cause dose-limiting rash at 250 and 300 mg, establishing the MTD as 200 mg QW (27) .
Combining MK-2206 with other therapies has shown synergistic antitumor effects in vitro (28) . The combination of an Akt inhibitor with an mTOR inhibitor was considered a rational duplex to investigate, as mTOR inhibition and Akt inhibition complement each other, and targeting both may produce more complete blockade of the PI3K pathway. Inhibition of Akt could abrogate the feedback induction that results from mTOR complex one (mTORC1) inhibition, and the mTOR inhibition could block distal PI3K pathway signaling at the level of the S6 ribosomal protein that is not effectively inhibited by Akt inhibition alone. In addition, Akt signals through mTOR-independent pathways as well as through mTOR-dependent pathways, and the mTOR-independent signaling is important for tumor cell survival, and thus important to inhibit separately from mTOR.
In the preclinical setting a number of in vitro and in vivo cancer models, including breast and prostate cancers, have shown increased sensitivity to the combination relative to single agents (29) (30) (31) . The combination is expected to be most active in tumors with PI3K pathway addiction resulting from mutations in genes such as PTEN or PIK3CA (which encodes the catalytic subunit alpha of phosphatidylinositol-3-kinase), and in other lesions where RAS/mitogen-activated protein kinase (MAPK) signaling is not constitutively active. It is thus important to identify with use of biomarkers those patients most likely to benefit from treatment with the ridaforolimus/MK-2206 combination. For breast cancer the biomarkers chosen were RAS gene signature and Ki67 analysis, and for prostate cancer PTEN loss was analyzed.
The RAS gene expression signature contains 147 genes that are coherently expressed across multiple cell-line models and human tumors (32) . A low RAS signature score correlates with high PI3K pathway dependency and better responsiveness to PI3K pathway inhibition (32 Within ER-positive breast cancer, the luminal B subset is associated with poor prognosis compared with luminal A tumors (33, 34) . Luminal B tumors have higher PI3K pathway activity and are characterized by a high rate of cell proliferation. The Ki67 labeling index has been commonly used to identify a high proliferation subset of patients with ER-positive breast cancer; recently published data have shown that a Ki67 >13.25% is able to distinguish luminal B from luminal A tumors, with a sensitivity of 72% and a specificity of 77% (35) . It is therefore possible to enrich the study population with patients who have high proliferation, "luminal B-like" tumors that may be more sensitive to ridaforolimus and MK-2206 combination owing to dependence on the PI3K pathway.
PTEN loss of expression is a suitable biomarker for PI3K pathway-sensitive prostate cancer. Loss or mutations of PTEN and loss of heterozygosity of the PTEN locus occur in a variety of human cancers, and drives PI3K pathway dependence which correlates with advanced disease and poor prognosis in some tumors, including prostate cancer (36, 37) . PTEN status has been associated with responsiveness to a number of anticancer agents and treatment outcome (38) . In prostate cancer cell lines, PTEN deficiency correlated with enhanced sensitivity to mTOR inhibition (39) . This phase I study was undertaken to define the DLTs and MTD of combination ridaforolimus and MK-2206 in patients with solid tumors, and to explore the antitumor activity of ridaforolimus plus MK-2206 in expansion cohorts of patients with breast and prostate cancer whose tumors were PI3K-pathway dependent.
Patients and Methods

Study Design
This 
Patients
The study enrolled male or female adult patients (≥18 years old) with histologically confirmed metastatic or locally advanced solid tumors, who had failed to respond to standard therapy, had progressed despite standard therapy, or for whom standard therapy did not exist. Patients were not permitted to have any medical conditions that The 3+3 dose-escalation scheme required an initial cohort of 3 patients to be enrolled at a given dose level. If 0/3 patients developed a DLT, escalation to the next dose level would occur. If 1/3 patients developed a DLT, another 3 patients would be enrolled at that dose level. Providing that 0 of these 3 new patients developed a DLT (to give 1/6 patients with a DLT at this dose level), escalation to the next dose level would occur. If ≥1 of the 3 new patients developed a DLT (to give 2/6 patients with a DLT), the dose-escalation stage of the trial would be terminated and the dose directly below the current dose would be considered the preliminary MTD. If ≥2 of 3 patients developed DLTs, the dose level would not be considered further and a lower dose would be explored. If the highest candidate dose was studied during dose escalation, and 0/3 or ≤1 of 6 toxicities were observed at that dose, then dose escalation would terminate with this finding.
The planned dose-escalation schedule involved 2 additional full dose levels (DL2 and DL3), and also allowed sublevel increments that increased either ridaforolimus or MK-2206. If DL1 was found to be tolerable, simultaneous escalation to DL1.1 DLTs observed in cycle 1 were used to determine escalation to the next dose level. If the current dose was found to be intolerable, lower dose levels could be explored. On this basis, a lower dose of ridaforolimus 10 mg PO QD×5/wk plus MK-2206 90 mg PO weekly was also administered, designated DL-1.
Confirmation of the preliminary MTD was based on enrolling additional patients within disease-specific cohorts (i.e., breast cancer and prostate cancer) to confirm the tolerability of the MTD. Patient recruitment continued until 14 patients were enrolled at 1 dose (Part A patients plus patients from the 2 disease-specific indications in Part B) with ≤3 of 14 patients experiencing a DLT. After MTD confirmation, additional biomarker-eligible patients (target enrollment, n = 12) within each disease-specific cohort were enrolled to allow evaluation of tumor response at the MTD.
End Points and Assessments
The primary safety end point was the DLT rate. Adverse events were graded and recorded throughout the study according to National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 4.0 (v4.0). Toxicities were characterized in terms of duration, intensity, and time to onset. Assessments included vital signs, electrocardiogram (at screening and 2 hours after dose administration on day 2, cycle 1), ECOG performance status, comprehensive ophthalmologic examination, laboratory measures, and medical history.
Serious adverse events were defined as any adverse event that occurred at any dose that: resulted in death, was life threatening, placed the patient at immediate risk of death from the experience as it occurred, resulted in a persistent or significant disability or incapacity, resulted in or prolonged an existing inpatient hospitalization, resulted in a congenital anomaly or birth defect in offspring of patient, was a new cancer, or was an overdose (whether accidental or intentional).
The primary efficacy end point for part B in this study was response rate, defined as the proportion of patients whose best response was partial response (PR) or complete response (CR) assessed according to RECIST v1.1 (40) . Tumors were imaged using either computed tomography (CT) or magnetic resonance imaging (MRI) at screening, every 2 cycles (±5 days) during treatment, and at the time of treatment discontinuation. Analysis of imaging was undertaken locally by the investigator and centrally by an independent imaging laboratory (ICON Imaging). For patients with prostate cancer, PSA levels were also used for response.
Biomarker Assays
The RAS signature assay utilized the industry-standard Affymetrix platform consisting of its standard hybridization incubator and fluidics wash station as well as the FDA-cleared GeneChip ® 3000Dx v.2 scanner (Affymetrix, Inc.). RNA was purified from formalin-fixed, paraffin-embedded (FFPE) tissue samples using standard procedures, and then amplified using a NuGEN Ovation ® FFPE amplification system (NuGEN Technologies). A fixed amount of input cDNA (3. 
Statistics
No formal statistical hypothesis was tested for the primary objective of defining DLT and MTD. Descriptive statistics summarizing the number and percentage of patients who experienced adverse events, as categorized in the NCI CTCAE v4.0, were generated for the overall patient population and by disease-specific cohort.
Research. 
The safety analysis population consisted of all patients who received at least 1 dose of study treatment. The primary population for the analysis of efficacy and biomarker data was the full analysis set, consisting of all patients who received at least 1 dose of study treatment and had baseline data for those analyses that required baseline data.
Results
Disposition and Baseline Characteristics
Thirty-five patients were enrolled in the trial from 7 centers in 4 countries (4 in the Eleven patients were enrolled into part A (dose escalation) of the trial; 7 treated at DL1 and 4 treated at DL-1. For enrollment into part B of the trial (expansion of biomarker-eligible patients), 124 patients with breast cancer and 68 patients with prostate cancer were prescreened. Of the 124 patients with breast cancer, 98 patients had biopsy tissue that was adequately evaluable; of these, 51 (52%) were biomarker eligible, 21 of the eligible consenting patients were screened, and 16 were enrolled into the trial (6 treated at DL1; 10 treated at DL-1). In addition, 1 patient with breast cancer from Part A (treated at DL1) was found to be biomarker eligible when tested after she had a clinical response, and is included in the tumor response results
(bringing the total number of breast cancer subjects analyzed for efficacy to 17). Of the 68 prescreened patients with prostate cancer, 40 had tissue that was evaluable, of which 24 exhibited loss of PTEN, and 8 patients were enrolled into the trial (4 at DL1, and 4 at DL-1).
Twenty-three of the 35 allocated patients (65.7%) discontinued from the study because of progressive disease. Five patients (14.3%) discontinued because of an adverse event, 3 patients (8.6%) withdrew consent, and 3 patients (8.6%) discontinued per physician decision. One patient in the DL-1 group continued in the extension phase after database lock for >6 months before discontinuing because of progressive disease.
With the exception of tumor type, baseline characteristics were similar for patients assigned to the 2 different dose levels ( Table 1 ). The median age was 55 (range, 20-84) years old, and the majority of enrolled patients were white (83%). The patient population was heavily pretreated; the median number of prior systemic regimens received was 5 (range, 0-11). Most patients had received previous chemotherapy (91.4%), and many had also received hormonal or biologic therapies ( Table 1) .
Dose-Limiting Toxicity and Maximum-Tolerated Dose
There were 14 DLT-evaluable patients treated at DL1. Of these, 5 patients Table 2) . Eighteen of the 35 treated patients (51.4%) experienced 1 or more serious adverse events. One patient treated at DL-1 experienced multiple drugrelated serious adverse events (grade 2 asthenia and rash, grade 3 stomatitis, and rectal hemorrhage). Two patients treated at DL1 experienced 1 or more drug-related serious adverse events, including grade 3 stomatitis (1 patient) and grade 4 ALT increase and AST increase (1 patient). There was 1 death due to malignant neoplasm progression, which was not considered drug related; this was reported during the safety follow-up period following treatment at DL-1 ( Table 2 ).
The most commonly reported drug-related adverse events at the MTD included rash (44.4%), stomatitis (38.9%), diarrhea (27.8%), decreased appetite (27.8%), fatigue (22.2%), asthenia (22.2%), and nausea (22.2%) ( Table 3) . Most adverse events were less than grade 3 in severity. Hyperglycemia was rare at the MTD (DL-1), occurring in just 1/18 patients (5.6%), but was observed in 6/17 patients (35.3%) at DL1.
Tumor Response
Discussion
This trial established the MTD for this drug combination to be ridaforolimus 10 mg QD×5 days/wk plus MK-2206 90 mg weekly. The combination was generally well tolerated at the MTD, with rash, stomatitis, diarrhea, and decreased appetite being the most common drug-related adverse events; most of these were mild or moderate in severity. Only a small percentage of adverse events were grade 3 or higher. In singleagent trials of ridaforolimus, the most commonly reported adverse events have been mouth sores (including stomatitis, mucositis, and mucosal inflammation), rash, anemia, infection, and fatigue (15) (16) (17) (18) 20) . Single-agent trials of MK-2206 have reported rash, fatigue, nausea, and vomiting as the most common adverse events, and mild to moderate myelosuppression is also common (25, 26) . Both agents have been associated with increased incidence of hyperglycemia (25, 41) . Stomatitis/mucositis was very common at the higher dose level (experienced by approximately 70% of patients at that dose); reducing the dose of ridaforolimus in the combination was associated with a lower incidence of stomatitis. Stomatitis and other oral toxicities are a class toxicity associated with mTOR inhibitors, and are often the DLT (42-44). High incidence rates (56%) of stomatitis or mucositis have also been reported in randomized clinical trials of the approved mTOR inhibitor everolimus in combination treatments for breast cancer (45, 46) . Patients should be educated about early detection and maintaining good preventative oral hygiene to minimize the risk of occurrence of this adverse event (41, 47, 48) .
Rash was the most commonly reported adverse event at the MTD in this trial, and mild to moderate rash (typically an acne-like dermatitis) has also been frequently reported in trials of mTOR inhibitors (41, 45, 46, 49) . Rash appeared to be more common at the lower dose level (44% of patients) than the higher dose level (24% of patients). It is unclear why this inverse relationship occurred, or whether it is a real event or an artifact of the dosing schedule. For example, it is possible that other toxicities that appear earlier than rash could compromise dose intensity in the highest dose level, thus impeding rash appearance. 
antitumor activity in hormone-receptor positive breast cancer at a reduced dose of 150 mg QW (27) . The need to lower ridaforolimus dose when combining with other agents has been reported previously. In patients with metastatic castration-resistant prostate cancer receiving ridaforolimus with the androgen receptor inhibitor bicalutamide, the starting ridaforolimus dose of 30 mg QD×5/wk had to be reduced in 64% of patients, leading to a median ridaforolimus dose of 21.6 mg QD×5/wk (22).
Ridaforolimus pharmacokinetic parameters were not significantly affected by bicalutamide coadministration, suggesting that the toxicity might be due to synergetic pharmacodynamic effects on PI3K/Akt/mTOR pathway inhibition rather than pharmacokinetic drug interactions (22). This is likely to be the case for the ridaforolimus/MK-2206 combination also, as both agents target the PI3K/Akt/mTOR pathway. This may be a limitation for combinations of agents that target the same intracellular pathways.
Despite the low MTD of ridaforolimus plus MK-2206 identified in our trial, the combination showed promising activity in heavily pretreated patients with hormonepositive and -negative breast cancer who exhibited PI3K pathway dependence based on low RAS signature score. Three patients out of 17 (18%) enrolled with biomarker eligibility had either PR or CR based on either investigator or central radiological review. These results in a heavily pretreated patient population offer a rationale for exploring the combination of ridaforolimus and MK-2206 in further studies in PI3K pathway-dependent breast cancer. Use of biomarkers to identify patients most likely to benefit from targeted treatment could help increase response rate and reduce the number of patients who experience the toxicity associated with treatment with no benefit. The RAS pathway signature comprises a 147-gene signature that includes at (32) . It has been shown to be superior to KRAS mutation status for predicting response to PI3K and RAS pathway inhibitors (32) . RAS pathway activation has been noted in many cell lines and tumor samples in the absence of mutations in KRAS, and the RAS pathway signature can predict sensitivity to inhibition of MEK and resistance to inhibition of Akt in preclinical models of cancer (32) . Implementing the low RAS pathway signature threshold in this study ruled out patients with MAPK pathway overactivation (which can lead to PI3K inhibition due to the strong interaction between the pathways), resulting in selection of patients with PI3K dependence who were most likely to get benefit from the combination regimen.
Limited activity (SD) was observed in patients with low PTEN prostate cancer. The lack of objective responses in this patient population mirrored the findings of synergistic antitumor activity observed for this combination in preclinical studies, in which the combination primarily resulted in tumor stasis rather than regression (31) .
Combination with other agents that target alternative signaling pathways, such as the ERK/MAPK pathway (50), may be feasible to explore for future treatment options.
In conclusion, the combination of ridaforolimus and MK-2206 shows promising activity in heavily pretreated patients with hormone-positive and -negative breast cancer exhibiting PI3K pathway dependence based on low RAS signature score. No responses were observed in patients with low-PTEN prostate cancer, but prolonged SD was seen in 2 patients. The combination was generally well tolerated, with the most common drug-related adverse events being mild to moderate rash, stomatitis, clincancerres.a Downloaded from
